Combination treatment with paclitaxel, carboplatin and cetuximab in maxillary sinus cancer: A case report

Morimoto,Masahiro; Takano,Masashi; Sato,Takehiko; Makino,Shujiroh

doi:10.3892/ol.2024.14226

Combination treatment with paclitaxel, carboplatin and cetuximab in maxillary sinus cancer: A case report

Authors:
- Masahiro Morimoto
- Masashi Takano
- Takehiko Sato
- Shujiroh Makino
View Affiliations

Affiliations: Department of Oral Diagnosis and Medicine, Hokkaido University Faculty of Dental Medicine, Sapporo, Hokkaido 060‑8586, Japan, Department of Dentistry and Oral Surgery, Hokuto Hospital, Obihiro, Hokkaido 080‑0833, Japan
Published online on: January 10, 2024 https://doi.org/10.3892/ol.2024.14226
Article Number: 93
Copyright: © Morimoto et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The standard treatment for maxillary sinus cancer is surgery; however, surgery for advanced cases often leads to significant aesthetic and functional disability. Combination treatment (induction chemotherapy) with paclitaxel, carboplatin and cetuximab (PCE) can be effective in head and neck cancer. The present study describes the case of a patient with advanced maxillary sinus cancer that was successfully treated using the PCE regimen. A 69‑year‑old man presented to the Department of Dentistry and Oral Surgery, Hokuto Hospital (Obihiro, Japan) with left buccal swelling and an irregular mass on the left maxillary gingiva. The lesion filled the ethmoid and maxillary sinus, and destroyed the pterygoid process. Numerous lymph node metastases were suspected in the bilateral cervical region. The patient was diagnosed with left maxillary sinus cancer T4aN2cM0 and treated with PCE. The size of the tumor was markedly reduced after the initial treatment. After six cycles of PCE, bioradiotherapy (BRT; 66 Gy/33 Fr) was performed for the remaining lesion, and a complete response was achieved. Ten months after BRT, the tumor recurred in the anterior wall of the left maxillary sinus, which was treated by partial maxillary resection and split‑thickness skin grafting. No local or cervical recurrence was observed 2 years after the surgery. These findings suggested that PCE could be considered as the first step for the treatment of highly advanced malignant tumors in the head and neck.

View Figures

View References

1	Dulguerov P, Jacobsen MS, Allal AS, Lehmann W and Calcaterra T: Nasal and paranasal sinus carcinoma: Are we making progress?: A series of 220 patients and a systematic review. Cancer. 92:3012–3029. 2001. View Article : Google Scholar : PubMed/NCBI
2	Ono T, Tanaka N, Umeno H, Chitose S, Shin B, Aso T, On K, Hattori C, Etoh H, Kakuma T and Abe T: Treatment outcomes of locally advanced squamous cell carcinoma of the maxillary sinus treated with chemoradioselection using superselective intra-arterial cisplatin and concomitant radiation: Implications for prognostic factors. J Craniomaxillofac Surg. 45:2128–2134. 2017. View Article : Google Scholar : PubMed/NCBI
3	Jeremic B, Nguyen-Tan P and Bamberg M: Elective neck irradiation in locally advanced squamous cell carcinoma of the maxillary sinus: A review. J Cancer Res Clin Oncol. 128:235–238. 2002. View Article : Google Scholar : PubMed/NCBI
4	Mundy EA, Neiders ME, Sako K and Greene GW: Maxillary sinus cancer: A study of 33 cases. J Oral Pathol Med. 14:27–36. 1985. View Article : Google Scholar : PubMed/NCBI
5	Cengiz AB, Uyar M, Comert E, Dursun E and Eryilmaz A: Sinonasal tract malignancies: Prognostic factors and surgery outcomes. Iran Red Crescent Med J. 15:e141182013.PubMed/NCBI
6	Won HS, Chun SH, Kim BS, Chung SR, Yoo IR, Jung CK, Kim YS, Sun DI, Kim MS and Kang JH: Treatment outcome of maxillary sinus cancer. Rare Tumors. 1:110–114. 2009. View Article : Google Scholar
7	Arosio AD, Turri-Zanoni M, Sileo G, Tirloni M, Volpi L, Lambertoni A, Margherini S, Mercuri A, Battaglia P, Cherubino M, et al: Maxillary sinus floor infiltration: Results from a series of 118 maxillary sinus cancers. Laryngoscope. 132:26–35. 2022. View Article : Google Scholar : PubMed/NCBI
8	Homma A, Oridate N, Suzuki F, Taki S, Asano T, Yoshida D, Onimaru R, Nishioka T, Shirato H and Fukuda S: Superselective high-dose cisplatin infusion with concomitant radiotherapy in patients with advanced cancer of the nasal cavity and paranasal sinuses: A single institution experience. Cancer. 115:4705–4714. 2009. View Article : Google Scholar : PubMed/NCBI
9	Kies MS, Holsinger FC, Lee JJ, William WN Jr, Glisson BS, Lin HY, Lewin JS, Ginsberg LE, Gillaspy KA, Massarelli E, et al: Induction chemotherapy and cetuximab for locally advanced squamous cell carcinoma of the head and neck: Results from a phase II prospective trial. J Clin Oncol. 28:8–14. 2010. View Article : Google Scholar : PubMed/NCBI
10	Tahara M, Kiyota N, Yokota T, Hasegawa Y, Muro K, Takahashi S, Onoe T, Homma A, Taguchi J, Suzuki M, et al: Phase II trial of combination treatment with paclitaxel, carboplatin and cetuximab (PCE) as first-line treatment in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (CSPOR-HN02). Ann Oncol. 29:1004–1009. 2018. View Article : Google Scholar : PubMed/NCBI
11	Takenaka M, Arai A, Yoshizawa K, Yoshimura K, Mitsuda J, Saburi S, Tsujikawa T, Sugiyama Y and Hirano S: Feasibility of combination of paclitaxel, carboplatin, and cetuximab as induction chemotherapy for advanced head and neck squamous cell carcinoma. Clin Oncol. 3:13302019.
12	Pfister DG, Spencer S, Adelstein D, Adkins D, Anzai Y, Brizel DM, Bruce JY, Busse PM, Caudell JJ, Cmelak AJ, et al: Head and neck cancers, version 2.2020, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 18:873–898. 2020. View Article : Google Scholar : PubMed/NCBI
13	Haddad RI, Massarelli E, Lee JJ, Lin HY, Hutcheson K, Lewis J, Garden AS, Blumenschein GR, William WN, Pharaon RR, et al: Weekly paclitaxel, carboplatin, cetuximab, and cetuximab, docetaxel, cisplatin, and fluorouracil, followed by local therapy in previously untreated, locally advanced head and neck squamous cell carcinoma. Ann Oncol. 30:471–477. 2019. View Article : Google Scholar : PubMed/NCBI
14	Enokida T, Ogawa T, Homma A, Okami K, Minami S, Nakanome A, Shimizu Y, Maki D, Ueda Y, Fujisawa T, et al: A multicenter phase II trial of paclitaxel, carboplatin, and cetuximab followed by chemoradiotherapy in patients with unresectable locally advanced squamous cell carcinoma of the head and neck. Cancer Med. 9:1671–1682. 2020. View Article : Google Scholar : PubMed/NCBI
15	Bauman J, Langer C, Quon H, Algazy K, Lin A, Desai A, Mutale F and Weiss J: Induction chemotherapy with cetuximab, carboplatin and paclitaxel for the treatment of locally advanced squamous cell carcinoma of the head and neck. Exp Ther Med. 5:1247–1253. 2013. View Article : Google Scholar : PubMed/NCBI
16	Forman R, Bhatia AK and Burtness B: Efficacy and toxicity of weekly paclitaxel, carboplatin, and cetuximab as induction chemotherapy or in cases of metastases or relapse for head and neck cancer in elderly or frail patients. J Clin Oncol. 39:6042. 2021. View Article : Google Scholar
17	Shirasu H, Yokota T, Kawakami T, Hamauchi S, Onozawa Y, Ogawa H, Onoe T, Mori K and Onitsuka T: Efficacy and feasibility of induction chemotherapy with paclitaxel, carboplatin and cetuximab for locally advanced unresectable head and neck cancer patients ineligible for combination treatment with docetaxel, cisplatin, and 5-fluorouracil. Int J Clin Oncol. 25:1914–1920. 2020. View Article : Google Scholar : PubMed/NCBI
18	Lefebvre JL, Pointreau Y, Rolland F, Alfonsi M, Baudoux A, Sire C, de Raucourt D, Malard O, Degardin M, Tuchais C, et al: Induction chemotherapy followed by either chemoradiotherapy or bioradiotherapy for larynx preservation: The TREMPLIN randomized phase II study. J Clin Oncol. 31:853–859. 2013. View Article : Google Scholar : PubMed/NCBI